1
Q
SNS fight or flight
A
inc. mental activity bronchiolar dilation inc. RR inc. glucose inc. fatty acids inc. blood flow to skeletal muscles dilated pupils inc. HR inc. CO inc. arterial BP
2
Q
PSNS rest and digest
A
eyes: accommodation for near vision: miosis
saliva: copious
Bronchi: constriction, inc. secretion
Heart: dec. rate, dec. BP
GI tract: inc. secretion, inc. peristalsis, dec. sphincter tone
Bladder: dec sphincter tone, inc. detrusor
3
Q
Muscarinic effects: SLUG BAM
A
Salivation, Secretions, Sweating Lacrimation Urination GI upset Bradycardia, Bronchoconstriction, BM Abd. cramps, anorexia Miosis
4
Q
Anticholinergic effects: ABCDS
A
Anorexia Blurry vision Constipation, confusion Dry mouth Sedation, stasis of urine
5
Q
REMS
A
required risk management plans that use risk minimization strategies to ensure benefits > risk of Rx
- if drug causes liver failure, REMS would include monitoring liver function
6
Q
direct-acting agonists
A
directly activate adrenergic receptors
7
Q
indirect-acting agonists
A
enhancing release or blocking reuptake of norepi
Pharmacology
flashcards
Decks in class (78)
# Cards
-
module 1 pharmacodynamics and pharmacokinetics46
-
Module 1 ADME20
-
Module 1 ADME (ME)14
-
module 1 pharmacokinetics24
-
Module 1 special populations17
-
module 1 synch16
-
Module 17 preg categories, drug scheduling14
-
module 17 drug regulation and monitoring18
-
module 6 autonomics45
-
module 6 adrenoreceptor antagonist13
-
module 6 cholinergic agonists24
-
week 2 synch7
-
Module 7 hypertensives29
-
module 7 beta blockers23
-
module 7 adrenergic agonists14
-
module 7 ACE inhibitors, angiotensin receptor blockers, renin inhibitors14
-
module 7 calcium channel blockers12
-
module 7 vasodilators and digoxin21
-
synch session modules 7 and 1021
-
module 10 lipid lowering meds30
-
module 8 antiarrhythmics class 120
-
module 8 antiarrhythmics class 2 and 322
-
module 8 antiarrhythmic class 417
-
module 9 antiplatelet meds23
-
module 9 warfarin17
-
module 9 anticoagulants24
-
Module 9 thrombolytics and reversal agents10
-
Module 2 immunology and eicosanoids25
-
module 2 antihistamines18
-
Module 2 anti-asthmatic drugs27
-
module 2 anti-inflammatory asthma agents17
-
module 2 management of asthma12
-
Module 2 gout34
-
Module 5 tobacco, alcohol, benzo34
-
module 5 stimulant abuse11
-
module 5 opiates and heroin27
-
module 4 non-opioid alagesics21
-
module 4 NSAIDS15
-
module 4 opioid characteristics15
-
module 4 opioid agents35
-
module 4 opioid tolerance and dependence14
-
module 4 adjuvant analgesics8
-
module 4 anti-rheumatic drugs34
-
modules 2,4,5 synch session15
-
module 3 antidepressants and neurotransmitters15
-
module 3 MAOI, SSRI, TCA19
-
module 3 SNRI, atypical antiD, serotonin receptor agonist35
-
Module 3 anti-migraine21
-
module 3 antiemetics19
-
module 3 seizure31
-
module 3 anticonvulsants42
-
Module 3 anti-parkinson24
-
module 3 antipsychotics24
-
module 3 atypical antipsychotic20
-
module 3 sedatives and hypnotics27
-
module 3 anti-alzheimer's drugs16
-
Module 13 agents affecting GI motility25
-
module 13 Upper GI tract, PUD, GERD14
-
module 13 PUD and GERD meds26
-
module 13 GERD meds 216
-
module 16 DM overview33
-
module 16 biguanides and TZD13
-
module 16 non-insulin meds21
-
module 16 non-insulin meds 217
-
module 16 hyperglycemia management and CV impact16
-
module 16 inhaled insulin5
-
module 16 hyperthyroid meds15
-
module 16 hypothyroid meds14
-
module 16 weight management17
-
module 16 wt management 219
-
module 16 osteoporosis overview14
-
module 16 antiresorptive agents, bone anabolic agents33
-
module 16 phosphate binders, Ca, Vit. D27
-
module 14 gonadal hormone inhibitors28
-
module 14 uterotonics11
-
module 14 birth control15
-
module 14 HRT estrogen16
-
module 14 HRT androgen and phosphodiesterase 5 inhibitors13
